Tonia C Carter1, Dietrich Rein2, Inken Padberg3, Erik Peter4, Ulrike Rennefahrt5, Donna E David6, Valerie McManus7, Elisha Stefanski8, Silke Martin9, Philipp Schatz10, Steven J Schrodi11. 1. Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. Electronic address: carter.tonia@mcrf.mfldclin.edu. 2. Metanomics Health GmbH, Tegeler Weg 33, 10589, Berlin, Germany. Electronic address: dietrich.rein@metanomics-health.de. 3. Center for Stroke Research Berlin, Charitéplatz 1, 10117, Berlin, Germany. Electronic address: inken.padberg@charite.de. 4. metanomics GmbH, Tegeler Weg 33, 10589, Berlin, Germany. Electronic address: erik.peter@metanomics.de. 5. metanomics GmbH, Tegeler Weg 33, 10589, Berlin, Germany. Electronic address: ulrike.rennefahrt@metanomics.de. 6. Integrated Research and Development Laboratory, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. Electronic address: david.donna@mcrf.mfldclin.edu. 7. Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. Electronic address: valeriedmcmanus@gmail.com. 8. Integrated Research and Development Laboratory, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. Electronic address: stefanski.elisha@mcrf.mfldclin.edu. 9. Blutspendedienst des Bayerischen Roten Kreuzes Gemeinnützige GmbH, Herzog-Heinrich-Strasse 2, 80336, München, Germany. Electronic address: s.martin@blutspendedienst.com. 10. Metanomics Health GmbH, Tegeler Weg 33, 10589, Berlin, Germany. Electronic address: philipp.schatz@metanomics-health.de. 11. Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. Electronic address: schrodi.steven@mcrf.mfldclin.edu.
Abstract
BACKGROUND: Accurate, early diagnosis of type 2 diabetes (T2D) would enable more effective clinical management and a reduction in T2D complications. Therefore, we sought to identify plasma metabolite and protein biomarkers that, in combination with glucose, can better predict future T2D compared with glucose alone. METHODS: In this case-control study, we used plasma samples from the Bavarian Red Cross Blood Transfusion Center study (61 T2D cases and 78 non-diabetic controls) for discovering T2D-associated metabolites, and plasma samples from the Personalized Medicine Research Project in Wisconsin (56 T2D cases and 445 non-diabetic controls) for validation. All samples were obtained before or at T2D diagnosis. We tested whether the T2D-associated metabolites could distinguish incident T2D cases from controls, as measured by the area under the receiver operating characteristic curve (AUC). Additionally, we tested six metabolic/pro-inflammatory proteins for their potential to augment the ability of the metabolites to distinguish cases from controls. RESULTS: A panel of 10 metabolites discriminated better between T2D cases and controls than glucose alone (AUCs: 0.90 vs 0.87; p=2.08×10(-5)) in Bavarian samples, and associations between these metabolites and T2D were confirmed in Wisconsin samples. With use of either a Bayesian network classifier or ridge logistic regression, the metabolites, with or without the proteins, discriminated incident T2D cases from controls marginally better than glucose in the Wisconsin samples, although the difference in AUCs was not statistically significant. However, when the metabolites and proteins were added to two previously reported T2D prediction models, the AUCs were higher than those of each prediction model alone (AUCs: 0.92 vs 0.87; p=3.96×10(-2) and AUCs: 0.91 vs 0.71; p=1.03×10(-5), for each model, respectively). CONCLUSIONS: Compared with glucose alone or with previously described T2D prediction models, a panel of plasma biomarkers showed promise for improved discrimination of incident T2D, but more investigation is needed to develop an early diagnostic marker.
BACKGROUND: Accurate, early diagnosis of type 2 diabetes (T2D) would enable more effective clinical management and a reduction in T2D complications. Therefore, we sought to identify plasma metabolite and protein biomarkers that, in combination with glucose, can better predict future T2D compared with glucose alone. METHODS: In this case-control study, we used plasma samples from the Bavarian Red Cross Blood Transfusion Center study (61 T2D cases and 78 non-diabetic controls) for discovering T2D-associated metabolites, and plasma samples from the Personalized Medicine Research Project in Wisconsin (56 T2D cases and 445 non-diabetic controls) for validation. All samples were obtained before or at T2D diagnosis. We tested whether the T2D-associated metabolites could distinguish incident T2D cases from controls, as measured by the area under the receiver operating characteristic curve (AUC). Additionally, we tested six metabolic/pro-inflammatory proteins for their potential to augment the ability of the metabolites to distinguish cases from controls. RESULTS: A panel of 10 metabolites discriminated better between T2D cases and controls than glucose alone (AUCs: 0.90 vs 0.87; p=2.08×10(-5)) in Bavarian samples, and associations between these metabolites and T2D were confirmed in Wisconsin samples. With use of either a Bayesian network classifier or ridge logistic regression, the metabolites, with or without the proteins, discriminated incident T2D cases from controls marginally better than glucose in the Wisconsin samples, although the difference in AUCs was not statistically significant. However, when the metabolites and proteins were added to two previously reported T2D prediction models, the AUCs were higher than those of each prediction model alone (AUCs: 0.92 vs 0.87; p=3.96×10(-2) and AUCs: 0.91 vs 0.71; p=1.03×10(-5), for each model, respectively). CONCLUSIONS: Compared with glucose alone or with previously described T2D prediction models, a panel of plasma biomarkers showed promise for improved discrimination of incident T2D, but more investigation is needed to develop an early diagnostic marker.
Authors: C J Hukshorn; W H Saris; M S Westerterp-Plantenga; A R Farid; F J Smith; L A Campfield Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: Susan van Dieren; Joline W J Beulens; Yvonne T van der Schouw; Diederick E Grobbee; Bruce Neal Journal: Eur J Cardiovasc Prev Rehabil Date: 2010-05
Authors: S G Wannamethee; J Tchernova; P Whincup; G D Lowe; A Rumley; K Brown; L Cherry; N Sattar Journal: Int J Obes (Lond) Date: 2007-02-13 Impact factor: 5.095
Authors: C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Christopher Papandreou; Mònica Bulló; Miguel Ruiz-Canela; Courtney Dennis; Amy Deik; Daniel Wang; Marta Guasch-Ferré; Edward Yu; Cristina Razquin; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Miquel Fiol; Liming Liang; Pablo Hernández-Alonso; Clary B Clish; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Saifur R Khan; Haneesha Mohan; Ying Liu; Battsetseg Batchuluun; Himaben Gohil; Dana Al Rijjal; Yousef Manialawy; Brian J Cox; Erica P Gunderson; Michael B Wheeler Journal: Diabetologia Date: 2019-01-15 Impact factor: 10.122
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602
Authors: Mi Lai; Ying Liu; Gabriele V Ronnett; Anne Wu; Brian J Cox; Feihan F Dai; Hannes L Röst; Erica P Gunderson; Michael B Wheeler Journal: PLoS Med Date: 2020-05-20 Impact factor: 11.069
Authors: Khyati Y Mehta; Hung-Jen Wu; Smrithi S Menon; Yassi Fallah; Xiaogang Zhong; Nasser Rizk; Keith Unger; Mark Mapstone; Massimo S Fiandaca; Howard J Federoff; Amrita K Cheema Journal: Oncotarget Date: 2017-08-18
Authors: Linda Ahonen; Sirkku Jäntti; Tommi Suvitaival; Simone Theilade; Claudia Risz; Risto Kostiainen; Peter Rossing; Matej Orešič; Tuulia Hyötyläinen Journal: Metabolites Date: 2019-09-14
Authors: German Tapia; Tommi Suvitaival; Linda Ahonen; Nicolai A Lund-Blix; Pål R Njølstad; Geir Joner; Torild Skrivarhaug; Cristina Legido-Quigley; Ketil Størdal; Lars C Stene Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 5.958